Reportlinker Adds Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, April 21, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global diabetic foot ulcer market. The report identifies the key trends shaping and driving the global diabetic foot ulcer market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global diabetic foot ulcer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimated the global diabetic foot ulcer (DFU) therapeutics market to be worth $1,154m in 2010. It is forecast to grow at a compound annual growth rate (CAGR) of 10.2% to reach $2,275m by 2017. DFU therapeutics market is contributed by DFI therapeutics market and DFU Wound healing products. The DFI therapeutic market holds the major share of $1,127m of the total DFU therapeutics market. While DFU wound healing therapeutics market is worth only $26m. This high growth forecast is primarily attributed to an increase in the diabetic patient population which will lead to increases in DFU incidence and prevalence, along with emergence of more therapeutic options. The strong product pipeline will complement the existing products by providing effective treatment options.
Scope
The report provides information on the key drivers and challenges of the diabetic foot ulcer market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) diabetic foot ulcer market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as angiotensin analog, topoisomerases inhibitor, PKC modulator, PDGF modulator, adenosine A2a receptor agonist, cytokines modulater, protein synthesis inhibitor, Antithrombin III activator, cell wall or cell membrane integrity disruptor, Immune system activator, plasmin activator, perivascular supporting agent, angiogenesis stimulator.
- Analysis of the current and future competition in the seven key countries diabetic foot ulcer market. Key market players covered are Pfizer Inc., Genaera Corporation and Cardiovascular Biotherapeutics, Inc.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the diabetic foot ulcer therapeutics market.
- Analysis of key recent licensing and partnership agreements in diabetic foot ulcer market
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global diabetic foot ulcer market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global diabetic foot ulcer market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global diabetic foot ulcer market landscape? – Identify, understand and capitalize.
Table of Contents
1 Table of contents
1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Diabetic Foot Ulcer (DFU) Therapeutics: Introduction 7
2.1 Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Symptoms 9
2.5 Diagnosis 10
2.5.1 History and Physical Examination 10
2.5.2 Laboratory Tests 10
2.6 Treatment and Management Pattern 10
2.6.1 Management of Co-morbidities 10
2.6.2 Evaluation of Vascular Status 10
2.6.3 Tissue Management 11
2.7 GlobalData Pipeline Report Guidance 12
3 DFU Therapeutics: Market Characterization 13
3.1 DFU Therapeutics Global Market Size 13
3.2 DFU Therapeutics Market Forecast 15
3.3 DFU Therapeutics Market Size – The US (2005-2010) 17
3.4 DFU Therapeutics Market Forecast – The US (2010-2017) 19
3.5 DFU Therapeutics Market Size – France (2005-2010) 21
3.6 DFU Therapeutics Market Forecast – France (2010-2017) 23
3.7 DFU Therapeutics Market Size – Germany (2005-2010) 25
3.8 DFU Therapeutics Market Forecast – Germany (2010-2017) 27
3.9 DFU Therapeutics Market Size - Italy (2005-2010) 29
3.10 DFU Therapeutics Market Forecast - Italy (2010-2017) 31
3.11 DFU Therapeutics Market Size – Spain (2005-2010) 33
3.12 DFU Therapeutics Market Forecast – Spain (2010-2017) 35
3.13 DFU Therapeutics Market Size – The UK (2005-2010) 37
3.14 DFU Therapeutics Market Forecast – The UK (2010-2017) 39
3.15 DFU Therapeutics Market Size - Japan (2005-2010) 41
3.16 DFU Therapeutics Market Forecast – Japan (2010-2017) 43
3.17 Drivers and Restraints for the DFU Therapeutics Market 45
3.17.1 Drivers of the DFU Therapeutics Market 45
3.17.2 Barriers for DFU Therapeutics Market 45
3.18 Opportunity and Unmet Need Analysis 46
3.19 Key Takeaway 46
4 DFU Therapeutics: Competitive Assessment 47
4.1 Overview 47
4.2 Strategic Competitor Assessment 47
4.3 Major Marketed Product Profiles in DFU Therapeutics Market 48
4.3.1 Invanz (ertapenam) 48
4.3.2 Regranex (becaplermin) 49
4.3.3 Zyvox (linezolid) 50
4.3.4 Zosyn (piperacillin/tazobactam) 51
4.4 Key Takeaway 52
5 DFU Therapeutics: Pipeline Assessment 53
5.1 Overview 53
5.2 Strategic Pipeline Assessment 53
5.2.1 Technology Trends Analytic Framework 53
5.3 DFU Therapeutics – Pipeline by Phases of Development 54
5.3.1 DFU Therapeutics – Phase III Pipeline 54
5.3.2 DFU Therapeutics – Phase II Pipeline 55
5.3.3 DFU Therapeutics – Phase I Pipeline 55
5.3.4 DFU Therapeutics – Preclinical/ Discovery Clinical Pipeline 55
5.4 DFU Therapeutics – Pipeline by Mechanism of Action 56
5.5 Technology Trends Analytic Framework 57
5.6 DFU Therapeutics– Most Promising Drugs under Clinical Development 58
5.7 Most Promising Drugs Profile 59
5.7.1 Pexiganan (pexiganan acetate) 59
5.7.2 Fragmin (Dalteparin Sodium) 59
5.7.3 CVBT-141B (FGF-1) 60
5.8 Key Takeaway 61
6 DFU Therapeutics: Clinical Trials Mapping 62
6.1 Clinical Trials by Region/Country (US, EU-5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Prominent Sponsors 65
6.5 Top Ten Companies Participating in Therapeutics Clinical Trials 66
7 DFU Therapeutics: Strategic Assessment 68
7.1 Key Events impacting the Future Market 68
7.2 Future Market Competition Scenario 68
8 DFU Therapeutics: Future Players 70
8.1 Introduction 70
8.2 Company Profiles 70
8.2.1 Pfizer Inc. 70
8.2.2 Genaera Corporation 74
8.2.3 Cardiovascular Biotherapeutics, Inc 75
8.2.4 Tabular Presentation Details of Other Companies in the Pipeline 76
9 DFU Therapeutics: Licensing & Partnership Deals 82
10 DFU Therapeutics: Appendix 84
10.1 Definitions 84
10.2 Acronyms 84
10.3 Research Methodology 85
10.3.1 Coverage 85
10.3.2 Secondary Research 85
10.3.3 Forecasting 86
10.3.4 Primary Research 89
10.3.5 Expert Panels 89
10.4 Contact Us 89
10.5 Disclaimer 89
10.6 Bibliography 90
List of Tables
1.1 List of Tables
Table 1: Wagner-Meggit Classification of DFU 7
Table 2: Antibiotics Regimen for DFI 11
Table 3: DFU Therapeutics, Major Market, Global, Revenue ($m), 2005–2010 14
Table 4: DFU Therapeutics, Major Market, Global, Forecast ($m), 2010–2017 16
Table 5: DFU Therapeutics, Major Market, The US, Revenue ($m), 2005–2010 18
Table 6: DFU Therapeutics, Major Market, The US, Forecast ($m), 2010–2017 20
Table 7: DFU Therapeutics, Major Market, France, Revenue ($m), 2005–2010 22
Table 8: DFU Therapeutics, Major Market, France, Forecast ($m), 2010–2017 24
Table 9: DFU Therapeutics, Major Market, Germany, Revenue ($m), 2005–2010 26
Table 10: DFU Therapeutics, Major Market, Germany, Forecast ($m), 2010–2017 28
Table 11: DFU Therapeutics, Major Market, Italy, Revenue ($m), 2005–2010 30
Table 12: DFU Therapeutics, Major Market, Italy, Forecast ($m), 2010–2017 32
Table 13: DFU Therapeutics, Major Market, Spain, Revenue ($m), 2005–2010 34
Table 14: DFU Therapeutics, Major Market, Spain, Forecast ($m), 2010–2017 36
Table 15: DFU Therapeutics, Major Market, The UK, Revenue ($m), 2005–2010 38
Table 16: DFU Therapeutics, Major Market, The UK, Forecast ($m), 2010–2017 40
Table 17: DFU Therapeutics, Major Market, Japan, Revenue ($m), 2005–2010 42
Table 18: DFU Therapeutics, Major Market, Japan, Forecast ($m), 2010–2017 44
Table 19: DFU Therapeutics Market, Global, Invanz Revenue ($), 2005-2010 48
Table 20: DFU Therapeutics Market, Global, Regranex Revenue ($), 2005-2010 50
Table 21: DFU Therapeutics Market, Global, Zyvox Revenue ($), 2005-2010 51
Table 22: DFU Therapeutics Market, Global, Zosyn Revenue ($), 2005-2010 52
Table 23: DFU Therapeutics - Major Marketed Product, 2010 52
Table 24: DFU Therapeutics –Phase III Pipeline, 2010 54
Table 25: DFU Therapeutics – Phase II Pipeline, 2010 55
Table 26: DFU Therapeutics –Phase I Pipeline, 2010 55
Table 27: DFU Therapeutics – Preclinical and Discovery Pipeline, 2010 55
Table 28: DFU Therapeutics Market, Most Promising Drugs Under Clinical Development, 2010 58
Table 29: DFU Therapeutics, Global, Clinical Trials by Country, 2010 62
Table 30: DFU Therapeutics, Global, Clinical Trials by Phase, 2010 63
Table 31: DFU Therapeutics, Global, Clinical Trials by Status of Development, 2010 64
Table 32: DFU Therapeutics, Major Markets, Key Sponsors, 2010 66
Table 33: DFU Therapeutics, Major Markets, Clinical Trials of Top Ten Companies by Phase, 2010 67
Table 34: Pfizer Inc – Metabolic Disorders Pipeline Products, 2010 72
Table 35: Pfizer, Inc. – DFU Pipeline Products, 2010 72
Table 36: Pfizer Pharmaceuticals-Deals, 2010 73
Table 37: Genaera Corporation – DFU Pipeline Products, 2010 74
Table 38: Genaera Corporation. – DFU Therapeutics Pipeline Products, 2010 74
Table 39: Genaera Corporation – Deals, 2010 75
Table 40: Cardiovascular Biotherapeutics, Inc.. – Metabolic Disorder Pipeline Products, 2010 75
Table 41: Cardiovascular Biotherapeutics, Inc. – DFU Pipeline Products, 2010 76
Table 42: Cardiovascular Biotherapeutics, Inc. - Deals, 2010 76
Table 43: DFU Therapeutics – Other Companies in the Pipeline, 2010 76
Table 44: DFU Therapeutics, Global, Deals, 2010 82
List of Figures
1.2 List of Figures
Figure 1: Progression of DFU 8
Figure 2: DFI Therapeutics, Major Market, Global, Revenue ($m), 2005–2010 13
Figure 3: DFU Wound Healing Therapeutics, Major Market, Global, Revenue ($m), 2005–2010 14
Figure 4: DFI Therapeutics, Major Market, Global, Forecast ($m), 2010–2017 15
Figure 5: DFU Wound Healing Therapeutics, Major Market, Global, Forecast ($m), 2010–2017 16
Figure 6: DFI Therapeutics Market, The US, Revenue ($m), 2005–2010 17
Figure 7: DFU Wound Healing Therapeutics Market, The US, Revenue ($m), 2005–2010 18
Figure 8: DFI Therapeutics Market, The US, Forecast ($m), 2010–2017 19
Figure 9: DFU Wound Healing Therapeutics Market, The US, Forecast ($m), 2010–2017 20
Figure 10: DFI Therapeutics Market, France, Revenue ($m), 2005–2010 21
Figure 11: DFU Wound Healing Therapeutics Market, France, Revenue ($m), 2005–2010 22
Figure 12: DFI Therapeutics Market, France, Forecast ($m), 2010–2017 23
Figure 13: DFU Wound Healing Therapeutics Market, France, Forecast ($m), 2010–2017 24
Figure 14: DFI Therapeutics Market, Germany, Revenue ($m), 2005–2010 25
Figure 15: DFU Wound Healing Therapeutics Market, Germany, Revenue ($m), 2005–2010 26
Figure 16: DFI Therapeutics Market, Germany, Forecast ($m), 2010–2017 27
Figure 17: DFU Wound Healing Therapeutics Market, Germany, Forecast ($m), 2010–2017 28
Figure 18: DFI Therapeutics Market, Italy, Revenue ($m), 2005–2010 29
Figure 19: DFU Wound Healing Therapeutics Market, Italy, Revenue ($m), 2005–2010 30
Figure 20: DFI Therapeutics Market, Italy, Forecast ($m), 2010–2017 31
Figure 21: DFU Wound Care Therapeutics Market, Italy, Forecast ($m), 2010–2017 32
Figure 22: DFI Therapeutics Market, Spain, Revenue ($m), 2005–2010 33
Figure 23: DFU Wound Care Therapeutics Market, Spain, Revenue ($m), 2005–2010 34
Figure 24: DFI Therapeutics Market, Spain, Forecast ($m), 2010–2017 35
Figure 25: DFU Wound Care Therapeutics Market, Spain, Forecast ($m), 2010–2017 36
Figure 26: DFI Therapeutics Market, The UK, Revenue ($m), 2005–2010 37
Figure 27: DFU Wound Care Therapeutics Market, The UK, Revenue ($m), 2005–2010 38
Figure 28: DFI Therapeutics Market, The UK, Forecast ($m), 2010–2017 39
Figure 29: DFU Wound Care Therapeutics Market, The UK, Forecast ($m), 2010–2017 40
Figure 30: DFI Therapeutics Market, Japan, Revenue ($m), 2005–2010 41
Figure 31: DFU Wound Care Therapeutics Market, Japan, Revenue ($m), 2005–2010 42
Figure 32: DFI Therapeutics Market, Japan, Forecast ($m), 2010–2017 43
Figure 33: DFU Wound Care Therapeutics Market, Japan, Forecast ($m), 2010–2017 44
Figure 34: Opportunity and Unmet Need in the DFU Therapeutics Market, 2010 46
Figure 35: Strategic Competitor Assessment of the Major Marketed Products in DFU Therapeutics Market, 2010 47
Figure 36: DFU Therapeutics - Pipeline by Phases of Development 54
Figure 37: DFU Therapeutics – Pipeline by Mechanism of Action (%), 2010 56
Figure 38: Technology Trends Analytic Framework of DFU Therapeutics Pipeline, 2010 57
Figure 39: Technology Trends Analytic Framework of DFU Therapeutics Pipeline, Description, 2010 58
Figure 40: DFU Therapeutics – Clinical Trials by Country, 2010 62
Figure 41: DFU Therapeutics, Major Markets – Clinical Trials by Phase, 2010 63
Figure 42: DFU Therapeutics, Major Markets, Clinical Trials by Development Status, 2010 64
Figure 43: DFU Therapeutics, Major Markets, Overall Sponsors, 2010 65
Figure 44: DFU Therapeutics, Major Markets, Key Sponsors, 2010 65
Figure 45: DFU Therapeutics, Major Markets, Clinical Trials of Top Ten Companies by Phase, 2010 66
Figure 46: DFU Therapeutics Market, Drivers and Restraints 2010 68
Figure 47: Implications for Future Market Competition in the DFU therapeutics Market, 2010 68
Figure 48: DFU Therapeutics Market, Clinical Pipeline by Company, 2010 70
Figure 49: GlobalData Market Forecasting Model 88
To order this report:
: Diabetic Foot Ulcer (DFU) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article